Akebia Therapeutics, Inc.AKBANASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 64% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

64%

Rating Distribution

Strong Buy

00%

Buy

764%

Hold

327%

Sell

19%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 361% higher.

Bear Case

$6.00

+326%

Consensus

$6.50

+361%

Bull Case

$7.00

+396%

Price Range11 analysts

Low

Consensus

High

$6.00

$7.00

Current Target

Current Price

$1.41

Upside to Target

$5.09

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.12(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+8.70%

EPS+61.89%

FY2028

Rev+21.82%

EPS+97.47%

FY2029

Rev+12.85%

EPS+12.82%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+8.4%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 28, 2024H.C. Wainwright

Akebia price target raised to $6 from $5 at H.C. Wainwright

Target:$6.00

+203.0%from $1.98

Mar 3, 2022Needham

Akebia Therapeutics (AKBA) Stock: $7 Price Target And Buy Rating

Target:$7.00

+164.2%from $2.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance